Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment. 1998

A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
Department of Paediatrics, Sophia Children's Hospital, Rotterdam, The Netherlands. boot@alkg.azr.nl

OBJECTIVE Osteopenia has been reported in adult patients with chronic renal failure (CRF). Only a few studies have been performed in children. The objective of this study was to evaluate bone mineral density (BMD), bone turnover, body composition in children with CRF and to study the effect of GH on these variables. METHODS Two groups were identified: patients with growth retardation who received GH (GH-group) and patients most of whom were not growth retarded who did not receive GH (no-GH-group). After an observation period of 6 months, the patients in the GH-group started GH treatment. Patients were studied every 6 months during 18 months. METHODS Thirty-six prepubertal patients (27 boys and 9 girls), mean age 7.9 years, with CRF participated in the study. The GH-group consisted of 17 patients of whom 14 completed one year treatment. The no-GH-group consisted of 19 patients, of whom 16 were followed for 6 months, 14 for 12 months and 13 for 18 months. METHODS Lumbar spine BMD, total body BMD and body composition were assessed by dual energy X-ray absorptiometry, compared to age-and sex-matched reference values of the same population and expressed as standard deviation scores (SDS). BMD of appendicular bone was measured by quantitative microdensitometry (QMD). Blood samples were obtained to assess bone metabolism and growth factors. RESULTS Baseline mean lumbar spine and total body BMD SDS of all patients were not significantly different from normal. Mean lumbar spine and total body BMD SDS did not change significantly in the GH-group during GH treatment. The change of QMD at the midshaft during the first 6 months of GH treatment was significantly smaller than during the observation period (P < 0.01). Height SDS and biochemical markers of both bone formation and bone resorption increased significantly during GH treatment; 1,25-dihydroxyvitamin D remained stable. Lean tissue mass increased (P < 0.001) and percentage body fat decreased (P < 0.01) during GH treatment. BMD, the biochemical markers of bone turnover which are independent of renal function, and body composition remained stable in the no-GH-group. CONCLUSIONS Mean lumbar spine and total body BMD of children with chronic renal failure did not differ from healthy controls. The lack of a GH-induced increase in 1,25-dihydroxyvitamin D levels, probably due to treatment with alpha-calcidol, might be linked to the absence of a response in BMD during GH treatment in children with chronic renal failure.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D010012 Osteogenesis The process of bone formation. Histogenesis of bone including ossification. Bone Formation,Ossification, Physiologic,Endochondral Ossification,Ossification,Ossification, Physiological,Osteoclastogenesis,Physiologic Ossification,Endochondral Ossifications,Ossification, Endochondral,Ossifications,Ossifications, Endochondral,Osteoclastogeneses,Physiological Ossification
D001823 Body Composition The relative amounts of various components in the body, such as percentage of body fat. Body Compositions,Composition, Body,Compositions, Body
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
August 1997, The Journal of clinical endocrinology and metabolism,
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
April 1994, Pediatric nephrology (Berlin, Germany),
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
January 2007, Pediatric nephrology (Berlin, Germany),
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
October 2015, Menopause (New York, N.Y.),
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
January 2002, Journal of pediatric endocrinology & metabolism : JPEM,
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
July 2000, Pediatric nephrology (Berlin, Germany),
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
March 2018, Menopause (New York, N.Y.),
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
September 1995, The Journal of pediatrics,
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
November 2003, The Journal of clinical endocrinology and metabolism,
A M Boot, and J Nauta, and M C de Jong, and J W Groothoff, and M R Lilien, and J A van Wijk, and J E Kist-van Holthe, and A C Hokken-Koelega, and H A Pols, and S M de Muinck Keizer-Schrama
January 2013, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!